Showing results (371-380 of 654) with videos related to
Sort By:
Pageof 66
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumorsCinta Hierro, Mònica Sánchez-Guixé, Gabi Tarcic, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast CancerMohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, et al.Journal of Gynecologic Oncology|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analysesJung-Yun Lee, Ana Oaknin, Luis Manso, et al.NPJ Breast Cancer|May 22, 2025
Predicting pathologic ≥N2 disease in women with breast cancerKerollos Nashat Wanis, Wenli Dong, Yu Shen, et al.Advances in Therapy|September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.Cancer Research Communications|February 9, 2024
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast CancerJonathan Goldberg, Na Qiao, Jennifer L Guerriero, et al.JCI Insight|December 27, 2016
Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapyJiha Kim, Pedro Correa de Sampaio, Donna Marie Lundy, et al.Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.Scientific Reports|January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.Pageof 66